Biosimilar Development News

  1. Celltrion Announces The Acquisition Of iQone Healthcare Switzerland, Further Building Its Expertise And Foothold In Europe 11/15/2024

    Celltrion, a global biopharmaceutical leader, announced its acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland.

  2. Beneva Unveils Its Proactive Prescription Drug Management Strategy 11/14/2024

    Beneva’s proactive management of prescription drug costs has generated annual savings of over $71M for its group insurance partners and plan members thanks to a four-pronged strategy consisting of mandatory biosimilar transition, pharmaceutical agreements, a prior authorization program and step therapy.

  3. #SaveBigWithBiosimilars Campaign Provides Sustainable Solutions For Employer-Sponsored Health Benefit Plans 11/14/2024

    Biosimilars Canada has launched a new #SaveBigWithBiosimilars campaign to educate Canadian businesses about the benefits of adopting biosimilar transition policies for their employee health benefit plans.

  4. Sandoz Opens New Device Development Center In Cambridge, UK 11/11/2024

    Sandoz, the global leader in generic and biosimilar medicines, today announced the opening of a state-of-the-art device development center in Cambridge, UK. Located at Cambridge Science Park, the new facility will serve as a global hub for developing advanced drug delivery devices that support the extensive Sandoz pipeline of affordable medicines.

  5. Henlius And SVAX Forge Strategic Partnership In The MENAT Market 11/8/2024

    On the morning of November 7, at the 7th China International Import Expo (CIIE), Henlius (2696.HK) entered into a strategic collaboration with AL-TIRYAQ AL-KHALAWI Medical Company ("SVAX"), a subsidiary entity of Saudi Arabia's prominent family business group in the healthcare sector, the Fakeeh Family.

  6. MilliporeSigma Invests $76 Million To Expand ADC Manufacturing For Novel Cancer Therapies 11/6/2024

    MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced a $76 million expansion of its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri. This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.

  7. European Medicines Agency Confirms Acceptance Of Marketing Authorization Application For AvT05, A Proposed Biosimilar To Simponi® (golimumab) 11/4/2024

    Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT05, Alvotech’s proposed biosimilar to Simponi® (golimumab), a biologic used to treat several chronic inflammatory diseases.

  8. Meitheal Pharmaceuticals Secures Exclusive Commercial Licensing Agreement For Three Biosimilars In The U.S. 10/31/2024

    Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., Ltd. (“HKF”) to market and distribute three biosimilars in the U.S. The agreement covers biosimilars for oncology medications pegfilgrastim and filgrastim as well as follitropin alpha in the fertility space.

  9. US FDA Accepts Biologics License Application (BLA) For HLX14, Biosimilar Candidate Of PROLIA/XGEVA (denosumab) 10/30/2024

    Shanghai Henlius Biotech, Inc. and Organon announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA (denosumab).

  10. CMS Grants Fresenius Kabi Permanent, Product-Specific Q-Code And Pass-Through Payment Status For Tyenne (tocilizumab-aazg) 10/29/2024

    Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code and granted pass-through payment status for Tyenne (tocilizumab-aazg).